Yes, a handsome upfront payment of 2 billion USD, and later, if clinical trials progress favorably, up to an additional 1 billion may follow. It’s worth noting that this was not a partnering agreement but an acquisition. Novartis acquired Synnovation’s subsidiary, which develops the breast cancer drug, with all its rights. Therefore, no royalties from drug sales are involved here.
2 Likes